Oxycodone-naltrexone: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 281 patients with moderate to severe chronic low back pain showed that a greater proportion of patients receiving ALO-02 achieved a

Read the full 313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE